ARCHIVES

Taxol Recommended For Second Line Therapy In Platinum-Resistant Metastatic Ovarian Cancer

This article is from The Cancer Letter archive.

Vol. 18 No. 45 | November 20, 1992

Download PDF Visit The Full Archive

Related Articles

User Fees Proposed For FDA Oversight Services; Industry Groups Call It “Tax On Innovations”

January 20, 1989

In Brief: Last Two NCAB Choices Named; Hellman Heads ASCO, Sartorelli Named President Of AACR

May 16, 1986

Preoperative Drug Combo Benefits HER-2 Breast Cancer

April 29, 2005

Obese Men More Likely To Have Aggressive Tumors

February 27, 2004

DCPC Advisors Okay Minority Based CCOPs, RFA In Native Americans

January 15, 1993

In Brief: Diagnostic Imaging Cost Declines By Half as Percentage Of Health Cost In 10 Years

January 11, 1985